Last checked at 5 Oct 2012 14:07

Port Erin Biopharma Investments Limited ("The Company")
Net Asset Value calculation for the fourth trading quarter to 30th September 2012
Â
Jim Mellon, Chairman, commented: -
"The Net Asset Value ("NAV") calculation for the Company as at closing on 30 September 2012 was 9.63 pence per share, including un-invested cash of £329,708. The portfolio is valued under IFRS at bid price. This quarter's NAV represents a useful increase from the previous valuation of 9.46 pence per share, including un-invested cash of £237,391. The revenue reserve has increased substantially following the deduction of listing expenses from the share premium account and represents a return of 16.75% on investments after operating costs."
 | Unaudited 15 September 2011 to 30 September 2012 £ | |
Fixed Assets | Â | Â |
 | Investments  | 2,859,129 |
Current Assets | Â | Â |
 | Debtors: amounts owing | 12,414 |
 | Un-invested cash  | 329,708 |
Current Liabilities | Â | Â |
 | Creditors: amounts due  | (23,400) |
 |  | 3,177,851 |
Capital and Reserves | Â | Â |
 | Share Capital | 33 |
 | Share Premium | 2,699,011 |
 | Capital reserve - realised | 0 |
 | Capital reserve - unrealised | 0 |
 | Revenue reserve  | 478,806 |
 | 3,177,850 | |
 | ||
Shares in Issue  | 33,000,000 | |
Net Asset Value per share   | 9.63 pence |
Â
--- ENDS ---
Â
Portfolio Details
Holdings |  £Value | Portfolio % |
 | 30/09/2012 |  |
Synergy Pharmaceuticals Inc. | 235,997 | 8.3% |
Pfizer Inc. | 227,368 | 8.0% |
Plethora Solutions Holdings | 199,963 | 7.0% |
Summit Corporation plc | 184,133 | 6.4% |
Gilead Sciences Inc. | 176,372 | 6.2% |
Novartis AG | 170,354 | 6.0% |
Arrowhead Research Corp. | 169,915 | 5.9% |
Astellas Pharmaceuticals Inc. | 157,268 | 5.5% |
Abbott Laboratories | 122,948 | 4.3% |
Nektar Therapeutics | 110,864 | 3.9% |
 | 1,755,182 | 61.4% |
 |  |  |
Aggregate remaining holdings below 3% of total portfolio | 1,103,947 Â | 38.6% Â |
 | 2,859,129 | 100.0% |
For further information, please contact:
Port Erin Biopharma Investments Ltd | Libertas Capital Corporate Finance Limited | Peterhouse Capital Limited |
The Company | Nomad | Broker |
Denham Eke +44 162 463 9396 | Sandy Jamieson +44 207 569 9650 | Jon Levinson +44 207 562 3350 |
Â